JPRN-jRCT2071220025
Completed
Phase 3
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
Tanaka Yoshiyuki0 sites63 target enrollmentJuly 8, 2022
ConditionsPneumococcal infection prevention
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Pneumococcal infection prevention
- Sponsor
- Tanaka Yoshiyuki
- Enrollment
- 63
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The participant may have underlying chronic conditions if they are assessed to be stable as per the investigator's judgment.
- •\- Is male or female, \=\>50 years of age, at the time of informed consent.
- •\- Is pneumococcal vaccine\-experienced, defined as prior receipt (\=\>1 year before enrollment)
Exclusion Criteria
- •\- has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1
- •\- has a known hypersensitivity to any vaccine components
- •\- has impaired immunological function
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-ITMERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.700
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsPneumococcal diseaseMedDRA version: 20.0Level: LLTClassification code 10035644Term: Pneumococcal infection NOSSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2021-006679-41-ESMerck Sharp & Dohme LLC700
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-FRMerck Sharp & Dohme LLC717
Completed
Phase 3
A Phase 3 Clinical Trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7® compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanomaNL-OMON31643Vical Incorporated15
Active, not recruiting
Not Applicable
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-BEVical Incorporated375